Rekognan, 500 mg/4 ml 4 ml 5 pcs

Pharmacological group:

Notropic drug

Pharmacotherapeutic group:

Notropic drug

Pharmacological action

Citicoline, as a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes repair of damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmission.

In brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, and also helps to reduce the duration of the recovery period.

Cyticoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as impaired memory, lack of initiative, difficulty in performing daily activities and self-care. It increases the level of attention and consciousness, and reduces the manifestation of amnesia.

Pharmacokinetics

Absorption

Cyticolin is well absorbed when taken orally. Absorption after oral administration is almost complete and bioavailability is approximately the same as after IV administration. After oral administration and parenteral administration the plasma concentration of choline is significantly increased.

Distribution

Cyticoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and citidine fractions into citidine nucleotides and nucleic acids. Citicoline penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fractions.

Metabolism

In IV and IM administration citicoline is metabolized in the liver to form choline and citidine.

Elimination

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and intestines and about 12% through the exhaled air.

Two phases can be distinguished in the urinary excretion of citicoline: a first phase lasting about 36 hours, during which the excretion rate decreases rapidly, and a second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled air – the excretion rate drops rapidly after about 15 h and then decreases much more slowly.

Indications

– Acute period of ischemic stroke (in the complex therapy);

– The recovery period of ischemic and hemorrhagic strokes;

– craniocerebral trauma (CTS), acute (as part of complex therapy) and recovery period;

– cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Active ingredient

Composition

The solution for intravenous and intramural administration is clear, colorless.

Associates:

Hydrochloric acid or sodium hydroxide to pH 6.5-7.5,

d/i water – up to 4 ml.

How to take, the dosage

The drug is administered by IV or IM.

In/v is administered as a slow IV injection (over 3-5 minutes, depending on the prescribed dose) or as an IV drip infusion (40-60 drops/minute).

The IV route of administration is preferable to the IV/m route. Repeated administration of the drug to the same site should be avoided when administered by IV.

Acute period of ischemic stroke and traumatic brain injury: 1000 mg every 12 hours from the first day after diagnosis. The duration of treatment is at least 6 weeks. In 3-5 days after the beginning of treatment (if swallowing function is not impaired) conversion to oral forms of Recognan® is possible.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of CHT, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg/day. The dose and duration of treatment depend on the severity of the symptoms. Oral forms of Recognan® may be used.

Dose adjustment is not necessary in elderly patients.

The solution in the ampoule is for single use. It should be used immediately after opening the ampoule.

The drug is compatible with all types of isotonic infusion solutions and dextrose solutions.

Interaction

Citicoline enhances the effects of levodopa.

Do not prescribe concomitantly with drugs containing meclofenoxate.

Special Instructions

Impact on driving and operating machinery

Patients should be cautious during treatment when performing potentially hazardous activities requiring increased attention and quick psychomotor reactions (including driving vehicles, operating moving machinery, work of a dispatcher, operator).

Contraindications

– vagotonia (predominance of tone of the parasympathetic part of the autonomic nervous system);

– rare hereditary diseases associated with fructose intolerance (for oral administration);

– childhood and adolescence under 18 years of age (due to lack of clinical data);

– hypersensitivity to the components of the drug.

There is no information about the relative contraindications for oral use of the drug.

Side effects

Frequency of adverse reactions: very rare (less than 1/10 000) (including individual cases).

Allergic reactions: rash, skin itching, anaphylactic shock.

Nervous system disorders: headache, dizziness, insomnia, agitation, hallucinations. In some cases the drug may stimulate the parasympathetic system and change BP for a short time.

Digestive system disorders: nausea, vomiting, diarrhea, decreased appetite, altered liver enzyme activity.

General reactions: fever, tremor, shortness of breath, numbness in paralyzed limbs, edema.

If any of these side effects are worsened or any other side effects are noted, the patient should inform the physician.

Overdose

Similarities